Cargando…

Warfarin Use in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review of Stroke and Bleeding Outcomes

BACKGROUND: Given the lack of clear indications for the use of warfarin in the treatment of atrial fibrillation (AF) in patients on hemodialysis and the potential risks that accompany warfarin use in these patients, we systematically reviewed stroke and bleeding outcomes in hemodialysis patients tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Chieh, Marcus, Laura Quinn, Patel, Priya, Battistella, Marisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652660/ https://www.ncbi.nlm.nih.gov/pubmed/29093823 http://dx.doi.org/10.1177/2054358117735532

Ejemplares similares

Warfarin and the Risk of Death, Stroke, and Major Bleeding in Patients With Atrial Fibrillation Receiving Hemodialysis: A Systematic Review and Meta-Analysis
por: Lei, Hong, et al.
Publicado: (2018)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Warfarin Use and Risk of Stroke in Patients With Atrial Fibrillation Undergoing Hemodialysis: A Meta-Analysis
por: Lee, Meng, et al.
Publicado: (2016)

Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin
por: Lai, Hoang M, et al.
Publicado: (2009)

Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty
por: Juma, Salima, et al.
Publicado: (2013)

The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation
por: Simon, Teresa A., et al.
Publicado: (2016)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

SAIL study of stroke, systemic embolism and bleeding outcomes with warfarin anticoagulation in non-valvular atrial fibrillation (S(4)-BOW-AF)
por: Harris, Daniel E, et al.
Publicado: (2023)

Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes
por: Gallagher, Arlene M, et al.
Publicado: (2014)

Stroke and Bleeding Risk in Atrial Fibrillation
por: Senoo, Keitaro, et al.
Publicado: (2014)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis
por: Tan, Jingwen, et al.
Publicado: (2016)

Direct Oral Anticoagulants vs. Warfarin in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Elfar, Sohil, et al.
Publicado: (2022)

Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2022)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
por: Molteni, Mauro, et al.
Publicado: (2014)

The use of warfarin in veterans with atrial fibrillation
por: Bravata, Dawn M, et al.
Publicado: (2004)

Warfarin for Prevention of Thrombosis Among Long-Term Care Residents with Atrial Fibrillation: Evidence of Continuing Low Use Despite Consideration of Stroke and Bleeding Risk
por: Reardon, Gregory, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation
por: Ghate, Sameer R., et al.
Publicado: (2011)

Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta‐analysis
por: Jiang, Hongcheng, et al.
Publicado: (2021)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke
Publicado: (2010)

Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management
por: Bahbahani, Hamad, et al.
Publicado: (2018)

Prescribing and Safety of Direct-Acting Oral Anticoagulants Compared to Warfarin in Patients with Atrial Fibrillation on Chronic Hemodialysis
por: Davis, Estella, et al.
Publicado: (2020)

Time in Therapeutic Range Using a Nomogram for Dose Adjustment of Warfarin in Patients on Hemodialysis With Atrial Fibrillation
por: Defoe, Kimberly, et al.
Publicado: (2021)

Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study
por: Wang, Shirley V, et al.
Publicado: (2016)

Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin
por: Blum, Daniel, et al.
Publicado: (2019)

The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study
por: Jun, Min, et al.
Publicado: (2015)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

Calciphylaxis in the Setting of Hemodialysis, Liver Cirrhosis, and Warfarin Therapy for Atrial Fibrillation: An Argument for Alternative Anti-Embolic Therapy
por: Medepalli, Vidya M, et al.
Publicado: (2020)

A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants
por: Claxton, J’Neka S., et al.
Publicado: (2018)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Associations of Warfarin Use with Risks of Ischemic Cerebrovascular Events and Major Bleeding in Patients with Hyperthyroidism-Related Atrial Fibrillation
por: Liu, Sian-De, et al.
Publicado: (2022)

All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
por: Gilligan, Adrienne M., et al.
Publicado: (2017)

Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care
por: Allan, Victoria, et al.
Publicado: (2017)

Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices
por: Ewen, Edward, et al.
Publicado: (2012)

Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks
por: Deitelzweig, Steve, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1s44bv4llavc21gu1k2efdo45m